Author:
Tostmann Alma,Boeree Martin J.,Peters Wilbert H.M.,Roelofs Hennie M.J.,Aarnoutse Rob E.,van der Ven André J.A.M.,Dekhuijzen P.N. Richard
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine
Reference15 articles.
1. World Health Organization. WHO report 2007. Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland: World Health Organization; 2007. Available at: http://www.who.int/tb/publications/global_report/2007/pdf/full.pdf [accessed 7 February 2008].
2. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis;Yee;Am J Respir Crit Care Med,2003
3. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis;Schaberg;Eur Respir J,1996
4. Drug-induced hepatotoxicity;Lee;N Engl J Med,1995
5. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin;Sarma;Am Rev Respir Dis,1986
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献